Corvus Pharmaceuticals, Inc. Just Filed Its Quarterly Report: 3. Net Loss per Shar...

3. Net Loss per Share

The following table shows the calculation of net loss per share (in thousands, except share and per share data):

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

    

2020

    

2019

    

Numerator:

  

 

  

  

 

  

Net loss - basic and diluted

$

(10,611)

$

(12,978)

$

(23,546)

$

(24,621)

Denominator:

 

 

  

 

 

  

Weighted average common shares outstanding

 

29,428,249

 

29,329,229

 

29,419,741

 

29,328,075

Less: weighted average common shares subject to repurchase

 

 

(20,079)

 

 

(26,570)

Weighted average common shares outstanding used to compute basic and diluted net loss per share

 

29,428,249

 

29,309,150

 

29,419,741

 

29,301,505

Net loss per share, basic and diluted

$

(0.36)

$

(0.44)

$

(0.80)

$

(0.84)

Weighted average common shares outstanding for the three and six months ended June 30, 2020 include 1,458,000 shares of common stock issuable on the conversion of pre-funded warrants described in Note 1.

The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

    

2020

    

2019

    

Common stock subject to repurchase

 

12,384

 

12,384

Outstanding options

5,561,098

 

4,157,154

5,561,098

 

4,157,154

Total shares of common stock equivalents

5,561,098

 

4,169,538

5,561,098

 

4,169,538

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Corvus Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh

Feedback